I am a
Home I AM A Search Login

Papers of the Week


December 1, 2022


Pediatr Allergy Immunol


http://www.ncbi.nlm.nih.gov/pubmed/36564878?dopt=Abstract


33


12

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.

Authors

Kamphuis E, Boesjes CM, Loman L, Bakker DS, Poelhekken M, Zuithoff NPA, Kamsteeg M, Romeijn GLE, van Wijk F, de Bruin-Weller MS, de Graaf M, Schuttelaar MLA
Pediatr Allergy Immunol. 2022 Dec; 33(12):e13887.
PMID: 36564878.

Abstract

Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and serum biomarkers in pediatric patients with moderate-to-severe AD in daily practice.